Table 1.
Synergistic analysis of the combination of alteronol and ADM on 4T1 cells.
| Alteronol + adriamycin | Cell line | Parameter | Fa30 | Fa50 | Fa70 | Fa90 |
|---|---|---|---|---|---|---|
| 4T1 | CI | 4.58417 | 1.49738 | 0.67398 | 0.32756 | |
| DRI (alteronol) | 1.29891 | 1.67896 | 2.17022 | 3.26654 | ||
| DRI (adriamycin) | 0.26217 | 1.10892 | 4.69044 | 46.6730 |
Cells were treated with alteronol with or without ADM for 48 h. CI and DRI values were calculated by CompuSyn software. Fa, effect levels. Fa30–Fa90, 30–90% efficiency percentage. CI, combination index; CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (Dx)1 and (Dx)2 represent the doses of drug 1 and 2 in a combination needed for achieving the same efficiency as that of the single drug 1 or 2 at D1 or D2, respectively, CI < 1,CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic effects, respectively. Dose reduction index (DRI) indicates the fold change of the dose for each drug to be reduced in a combination compared to a single drug at a given effect. The greater the DRI value, the more the dose of a single drug should be reduced to achieve the same effect. The DRIs of alteronol and ADM are greater than 1, indicating a synergistic effect for the combined treatment.